Skip to content
The Cancer History Project
HOME
ABOUT
THE CANCER HISTORY PROJECT
THE CANCER LETTER
EDITORIAL BOARD
SPONSORS
CONTRIBUTORS
TCL ARCHIVES
LATEST ARTICLES
Search for:
Search
ARCHIVES
Phase III Trial of Talimogene Laherparepvec Meets Response Rate Primary Endpoint
This article is from
The Cancer Letter
archive.
Vol. 36 No. 3 | March 29, 2013
Download PDF
Visit The Full Archive
Related Articles
TCL Archive
ACS Says 41 Percent Survive 5 Years
January 2, 1981
TCL Archive
DeVita, Moertel Debate Timing Of Levamisole Update
February 16, 1990
TCL Archive
NCI’s Breast Cancer Screening Guidelines Released In Draft
September 24, 1993
TCL Archive
MRI, 3D Ultrasound Combination Can Guide Prostate Biopsies
December 28, 2012
TCL Archive
DCT Board Okays Concepts For New Radiation Studies
June 12, 1987
TCL Archive
Cancer Groups Urge Support For Comprehensive Cancer Care Legislation.
June 29, 2007